Best of cannabinoid science this week...
A clinical study shows that 50 milligrams CBD for eight weeks caused significant improvements in sleep quality & enhanced the functioning of natural killer immune cells Eight Weeks of Daily Cannabidiol Supplementation Improves Sleep Quality and Immune Cell Cytotoxicity https://pubmed.ncbi.nlm.nih.gov/37836465/
In people undergoing chemotherapy cancer treatments, 600 milligrams of CBD per day helped to prevent neuropathy
Oral cannabidiol for prevention of chemotherapy-induced peripheral neuropathy
In dogs with drug resistant epilepsy, 9 mg/kg/day of CBD effectively reduced seizures, though the liver enzyme activities should be monitored & side effects of decreased appetite & increased vomiting should be watched for The efficacy and safety of cannabidiol as adjunct treatment for drug-resistant idiopathic epilepsy in 51 dogs: A double-blinded crossover study https://pubmed.ncbi.nlm.nih.gov/37889215/
On potential drug interactions of THC & CBD, though these “are probably of little importance at low or moderate doses” Drug Interactions of Tetrahydrocannabinol and Cannabidiol in Cannabinoid Drugs: Recommendations for Clinical Practice https://pubmed.ncbi.nlm.nih.gov/37874128/
A special series of articles on PEA for neuroinflammation & pain Special Issue "To Go Where Nature Leads: Focus on Palmitoylethanolamide and Related ALIAmides As Innovative Approach to Neuroinflammatory and Pain-Related Disease States in Honor of Doctor Francesco Della Valle" https://www.mdpi.com/journal/biomolecules/special_issues/Palmitoylethanolamide
On the actions of PEA & OEA via regulation of genetic transcription Editorial: The paracannabinoid system: endocannabinoid-like lipids and their functions https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646612/
A review of natural compounds that modulate the endocannabinoid system Exploring the therapeutic potential of natural compounds modulating the endocannabinoid system in various diseases and disorders: review https://pubmed.ncbi.nlm.nih.gov/37906390/
A great review of the gut-brain- endocannabinoid axis Neuro-Gastro-Cannabinology: A Novel Paradigm for Regulating Mood and Digestive Health https://pubmed.ncbi.nlm.nih.gov/37920559/
And a review of the history of cannabinoids for GI tract disorders & their future Pharmacohistory of Cannabis Use-A New Possibility in Future Drug Development for Gastrointestinal Diseases https://pubmed.ncbi.nlm.nih.gov/37834122/
For visceral pain, a review of using the non-intoxicating cannabinoids Non-Intoxicating Cannabinoids in Visceral Pain https://pubmed.ncbi.nlm.nih.gov/37883662/
In people with advanced cancer, a review of using cannabis to support their gut health Supporting gut health with medicinal cannabis in people with advanced cancer: potential benefits and challenges https://pubmed.ncbi.nlm.nih.gov/37884682/
A review of using cannabinoids for epilepsy & seizure disorders Cannabinoid treatments in epilepsy and seizure disorders https://pubmed.ncbi.nlm.nih.gov/37882730/
In a mouse model of psoriasis, using topical CBD significantly lowered psoriasis scores Cannabidiol-Loaded Lipid-Stabilized Nanoparticles Alleviate Psoriasis Severity in Mice: A New Approach for Improved Topical Drug Delivery https://pubmed.ncbi.nlm.nih.gov/37836750/
In heart tissue, CBD & THCV lowered inflammation Non-Psychoactive Phytocannabinoids Inhibit Inflammation-Related Changes of Human Coronary Artery Smooth Muscle and Endothelial Cells https://pubmed.ncbi.nlm.nih.gov/37830604/
In a rat model of hypertension from high blood pressure coming from the lungs, CBD lowered fibrosis (scarring) Cannabidiol alleviates right ventricular fibrosis by inhibiting the transforming growth factor β pathway in monocrotaline-induced pulmonary hypertension in rats https://pubmed.ncbi.nlm.nih.gov/37187449/
In a tissue model of intestinal inflammation, a number of cannabinoids lowered inflammation & altered genetic transcription, the strongest being THC Phytocannabinoids Reduce Inflammation of Primed Macrophages and Enteric Glial Cells: An In Vitro Study https://pubmed.ncbi.nlm.nih.gov/37834076/
In an animal model of Parkinson's disease, the terpene beta caryophyllene decrease neuro inflammation & protected the dopamine neurons via inhibition of the inflammasome β-Caryophyllene decreases neuroinflammation and exerts neuroprotection of dopaminergic neurons in a model of hemiparkinsonism through inhibition of the NLRP3 inflammasome https://pubmed.ncbi.nlm.nih.gov/37924806/
In a thesis project using two mouse models of schizophrenia, HU-580 (a stable version of CBDA) seemed to help via the CB1 & 5-HT1A serotonin receptor CANNABIDIOLIC ACID METHYL ESTER (HU-580) TREATMENT IN TWO PRECLINICAL MODELS OF SCHIZOPHRENIA: THE ROLE OF CB1 AND 5-HT1A RECEPTORS https://research.library.mun.ca/16101/1/converted.pdf